Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer

Kurman, 2016, vol. 186, 733 Vang, 2009, Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems, Adv Anat Pathol, 16, 267, 10.1097/PAP.0b013e3181b4fffa Bell, 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 Amin Vaughan, 2011, Rethinking ovarian cancer: recommendations for improving outcomes, Nat Rev Canc, 11, 719, 10.1038/nrc3144 Garcia-Soto, 2012, Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma?, Am J Obstet Gynecol, 206, 242.e1-5, 10.1016/j.ajog.2011.08.022 Timmers, 2010, Understanding the problem of inadequately staging early ovarian cancer, Eur J Canc, 46, 880, 10.1016/j.ejca.2009.12.012 Ledermann, 2013, Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 24, vi24, 10.1093/annonc/mdt333 Trimbos, 2003, International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase iii trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma, JNCI J Natl Cancer Inst, 95, 105, 10.1093/jnci/95.2.113 Trimbos, 2010, Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial, J Natl Cancer Inst, 102, 982, 10.1093/jnci/djq149 Collinson, 2014, Optimal treatment of early-stage ovarian cancer, Ann Oncol, 25, 1165, 10.1093/annonc/mdu116 Colombo, 2019, ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease, Ann Oncol Off J Eur Soc Med Oncol, 30, 672, 10.1093/annonc/mdz062 Chan, 2010, The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a gynecologic oncology group study, Gynecol Oncol, 116, 301, 10.1016/j.ygyno.2009.10.073 Mannel, 2011, A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a gynecologic oncology group study, Gynecol Oncol, 122, 89, 10.1016/j.ygyno.2011.03.013 du Bois, 2009, Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials, Cancer, 115, 1234, 10.1002/cncr.24149 Vergote, 2010, Neoadjuvant chemotherapy or primary surgery in stage iiic or iv ovarian cancer, N Engl J Med, 363, 943, 10.1056/NEJMoa0908806 Bookman, 2009, Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup, J Clin Oncol, 27, 1419, 10.1200/JCO.2008.19.1684 Bookman, 2010, The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer, vii211 Möbus, 2007, Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT, J Clin Oncol, 25, 4187, 10.1200/JCO.2006.09.7527 Walker, 2019, Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology/gynecologic oncology group study, J Clin Oncol, 37, 1380, 10.1200/JCO.18.01568 Katsumata, 2013, Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial, Lancet Oncol, 14, 1020, 10.1016/S1470-2045(13)70363-2 Chan, 2016, Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer, N Engl J Med, 374, 738, 10.1056/NEJMoa1505067 Clamp, 2019, Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial, Lancet, 394, 2084, 10.1016/S0140-6736(19)32259-7 Vasey, 2004, Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma, J Natl Cancer Inst, 96, 1682, 10.1093/jnci/djh323 Pignata, 2011, Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial, J Clin Oncol, 29, 3628, 10.1200/JCO.2010.33.8566 Yoneda Huang, 2000, Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8, Canc Res, 60 Burger, 2011, Incorporation of bevacizumab in the primary treatment of ovarian cancer, N Engl J Med, 365, 2473, 10.1056/NEJMoa1104390 Perren, 2011, A phase 3 trial of bevacizumab in ovarian cancer, N Engl J Med, 365, 2484, 10.1056/NEJMoa1103799 Oza, 2015, Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, Lancet Oncol, 16, 928, 10.1016/S1470-2045(15)00086-8 González Martín, 2019, Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer, Gynecol Oncol, 152, 53, 10.1016/j.ygyno.2018.08.036 Randall, 2013, Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab, Gynecol Oncol, 130, e33, 10.1016/j.ygyno.2013.04.139 Pfisterer, 2021, J Clin Oncol, 39, 10.1200/JCO.2021.39.15_suppl.5501 Aghajanian, 2012, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, J Clin Oncol, 30, 2039, 10.1200/JCO.2012.42.0505 Pujade-Lauraine, 2014, Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial, J Clin Oncol, 32, 1302, 10.1200/JCO.2013.51.4489 Pignata, 2021, Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial, Lancet Oncol, 22, 267, 10.1016/S1470-2045(20)30637-9 Konstantinopoulos, 2015, vol. 5, 1137 Iijima, 2017, Genome-wide analysis of gynecologic cancer: the cancer genome atlas in ovarian and endometrial cancer (Review), vol. 13, 1063 Moschetta, 2016, BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer, Ann Oncol, 27, 1449, 10.1093/annonc/mdw142 Elvin, 2017, Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC), J Clin Oncol, 35, 10.1200/JCO.2017.35.15_suppl.5512 Ledermann, 2012, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, N Engl J Med, 366, 1382, 10.1056/NEJMoa1105535 Ledermann, 2016, Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial, Lancet Oncol, 17, 1579, 10.1016/S1470-2045(16)30376-X Pujade-Lauraine, 2017, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 18, 1274, 10.1016/S1470-2045(17)30469-2 Mirza, 2016, Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, N Engl J Med, 375, 2154, 10.1056/NEJMoa1611310 Coleman, 2017, Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 390, 1949, 10.1016/S0140-6736(17)32440-6 Friedlander, 2018, Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy, Br J Cancer, 119, 1075, 10.1038/s41416-018-0271-y Poveda, 2021, Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 22, 620, 10.1016/S1470-2045(21)00073-5 Moore, 2018, Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer, N Engl J Med, 379, 2495, 10.1056/NEJMoa1810858 Banerjee, 2020, 811MO maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1, Ann Oncol, 10.1016/j.annonc.2020.08.950 Coleman, 2019, Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer, N Engl J Med, 381, 2403, 10.1056/NEJMoa1909707 Ray-Coquard, 2019, Olaparib plus bevacizumab as first-line maintenance in ovarian cancer, N Engl J Med, 381, 2416, 10.1056/NEJMoa1911361 González-Martín, 2019, Niraparib in patients with newly diagnosed advanced ovarian cancer, N Engl J Med, 381, 2391, 10.1056/NEJMoa1910962 Armstrong, 2021, Ovarian cancer, version 2.2020, JNCCN J Natl Compr Cancer Netw, 19, 191, 10.6004/jnccn.2021.0007 Colombo, 2021, Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO clinical practice guidelines, Ann Oncol Off J Eur Soc Med Oncol, 10.1016/j.annonc.2021.07.004 D'Andrea, 2018, vol. 71, 172 Lee, 2020, vol. 12, 1 Miller, 2020, ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer, Ann Oncol, 31, 1606, 10.1016/j.annonc.2020.08.2102 Darvin, 2018, Immune checkpoint inhibitors: recent progress and potential biomarkers, vol. 50, 165 Matulonis, 2019, Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study, Ann Oncol Off J Eur Soc Med Oncol, 30, 1080, 10.1093/annonc/mdz135 Ledermann, 2020, Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 javelin ovarian 100 trial, Gynecol Oncol, 159, 13, 10.1016/j.ygyno.2020.06.025 Moore, 2020, LBA31 primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC), Ann Oncol, 10.1016/j.annonc.2020.08.2261 Moore, 2021, Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase iii trial (IMagyn050/GOG 3015/ENGOT-OV39), J Clin Oncol, 39, 1842, 10.1200/JCO.21.00306 Stewart, 2018, vol. 78, 6717 McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage iii and stage iv ovarian cancer, N Engl J Med, 334, 1, 10.1056/NEJM199601043340101 Piccart, 2000, Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J Natl Cancer Inst, 92, 699, 10.1093/jnci/92.9.699